PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
75.25
-0.92 (-1.21%)
Jan 23, 2026, 4:00 PM EST - Market closed
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $211.01M in the quarter ending September 30, 2025, with 7.23% growth. This brings the company's revenue in the last twelve months to $1.78B, up 97.54% year-over-year. In the year 2024, PTC Therapeutics had annual revenue of $806.78M, down -13.97%.
Revenue (ttm)
$1.78B
Revenue Growth
+97.54%
P/S Ratio
3.31
Revenue / Employee
$1,894,728
Employees
939
Market Cap
6.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
| Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
| Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
| Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
| Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
| Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
| Dec 31, 2018 | 264.73M | 70.34M | 36.19% |
| Dec 31, 2017 | 194.39M | 111.69M | 135.04% |
| Dec 31, 2016 | 82.71M | 45.94M | 124.95% |
| Dec 31, 2015 | 36.77M | 11.52M | 45.64% |
| Dec 31, 2014 | 25.25M | -9.45M | -27.24% |
| Dec 31, 2013 | 34.70M | 750.00K | 2.21% |
| Dec 31, 2012 | 33.95M | -71.47M | -67.80% |
| Dec 31, 2011 | 105.41M | 100.45M | 2,022.34% |
| Dec 31, 2005 | 4.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protagonist Therapeutics | 209.22M |
| Rhythm Pharmaceuticals | 174.33M |
| ImmunityBio | 82.56M |
| Kymera Therapeutics | 43.74M |
| CRISPR Therapeutics AG | 38.34M |
| Crinetics Pharmaceuticals | 1.54M |
PTCT News
- 11 days ago - PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference - PRNewsWire
- 15 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan - PRNewsWire
- 5 weeks ago - PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 7 weeks ago - PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript - Seeking Alpha
- 7 weeks ago - Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - GlobeNewsWire